51S Stock Chart & Stats
€0.14
€0.00(0.00%)
At close: 4:00 PM EDT
€0.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)1.09K
Market Cap
€1.66M
Enterprise Value€77.99
Total Cash (Recent Filing)€897.42K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding243,454,380
10 Day Avg. Volume50
30 Day Avg. Volume1,090
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.41
Price to Sales (P/S)1.94
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€19.41M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces interest obligations and refinancing exposure, giving Cynata greater flexibility while it develops clinical programs. Although the capital base has weakened, the absence of leverage avoids an additional fixed claim on cash and may preserve strategic funding choices over the next several quarters.
High Gross MarginsNear-100% gross margins in several years indicate that the underlying revenue, when generated, carries limited direct cost burden. If Cynata can expand or commercialize its programs, this structure could support attractive contribution economics, though operating costs currently absorb the benefit.
Scalable Cell-therapy PlatformAn off-the-shelf iPSC-derived platform designed for scaled MSC production could support repeatable development across several inflammatory and immune-mediated indications. This multi-program structure offers potential diversification and broader commercialization opportunities than a single-asset biotechnology model.
Bears Say
Persistent Operating LossesLarge losses relative to the revenue base show that Cynata has not yet achieved operating scale or earnings sustainability. Continued negative margins can consume capital needed for clinical development and leave future progress dependent on successfully advancing candidates toward partnering or commercialization.
Ongoing Cash BurnRecurring negative operating and free cash flow means the business is not currently funding itself through operations. Even with a lower burn rate in 2026, continued cash consumption and reliance on external funding can constrain development plans and increase financing pressure over the medium term.
Deteriorating Capital BaseThe sharp reduction in assets and the shift to negative equity indicate substantial cumulative financial deterioration. A diminished capital base can reduce resilience, limit internal funding capacity, and make it harder to sustain clinical operations without additional capital or commercially meaningful partnerships.
Cynata Therapeutics Limited News
51S FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was €0.06 and its highest was €0.24 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is €1.66M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Feb 25, 2027 which is in 160 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Aug 31, 2026. The company reported -€0.017 earnings per share for the quarter.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 243,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -€0.017 in its last earnings report. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:51S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:51S Sentiment 68%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-80.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―